279 related articles for article (PubMed ID: 29183294)
1. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
Ikeda S; Yoshioka H; Ikeo S; Morita M; Sone N; Niwa T; Nishiyama A; Yokoyama T; Sekine A; Ogura T; Ishida T
BMC Cancer; 2017 Nov; 17(1):797. PubMed ID: 29183294
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Karakus A; Isikdogan A
J BUON; 2012; 17(3):533-6. PubMed ID: 23033295
[TBL] [Abstract][Full Text] [Related]
3. Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?
Kato T; Morise M; Ando M; Kojima E; Ogasawara T; Suzuki R; Shindoh J; Matsumoto M; Sugino Y; Ogawa M; Nozaki Y; Hase T; Kondo M; Saito H; Hasegawa Y
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1629-40. PubMed ID: 27166967
[TBL] [Abstract][Full Text] [Related]
4. Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients.
Kitazawa H; Takeda Y; Naka G; Sugiyama H
Sci Rep; 2019 Dec; 9(1):19872. PubMed ID: 31882700
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more.
Tamiya A; Naito T; Ono A; Ayabe E; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
Lung Cancer; 2011 Feb; 71(2):173-7. PubMed ID: 20570388
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
de Marinis F; Rossi A; Di Maio M; Ricciardi S; Gridelli C;
Lung Cancer; 2011 Jul; 73(1):1-10. PubMed ID: 21440325
[TBL] [Abstract][Full Text] [Related]
7. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
10. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
11. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
[TBL] [Abstract][Full Text] [Related]
12. Changes of serum albumin level and systemic inflammatory response in inoperable non-small cell lung cancer patients after chemotherapy.
Wang X; Han H; Duan Q; Khan U; Hu Y; Yao X
J Cancer Res Ther; 2014; 10(4):1019-23. PubMed ID: 25579547
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
Paz-Ares LG; Zimmermann A; Ciuleanu T; Bunn PA; Antonio BS; Denne J; Iturria N; John W; Scagliotti GV
Lung Cancer; 2017 Feb; 104():45-51. PubMed ID: 28212999
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.
Tanriverdi O; Avci N; Oktay E; Kalemci S; Pilanci KN; Cokmert S; Menekse S; Kocar M; Sen CA; Akman T; Ordu C; Goksel G; Meydan N; Barutca S
Asian Pac J Cancer Prev; 2015; 16(14):5971-6. PubMed ID: 26320482
[TBL] [Abstract][Full Text] [Related]
15. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
17. NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
J Chemother; 2016 Jun; 28(3):225-9. PubMed ID: 25971309
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
Riggs H; Jalal SI; Baghdadi TA; Bhatia S; McClean J; Johnson C; Yu M; Taber D; Harb W; Hanna N
Clin Lung Cancer; 2013 May; 14(3):224-9. PubMed ID: 23102811
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
20. Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer.
Sim SH; Kim YJ; Kim SH; Keam B; Kim TM; Lee SH; Kim DW; Heo DS; Lee JS
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1073-81. PubMed ID: 25410789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
